Prescription Drug Affordability Boards and the Impact on Cancer Care
ACS CAN has long fought for public policies that support the availability and affordability of medically necessary prescription drugs.
Comments to CMS Regarding National Coverage Decision for Next-Generation Sequencing (NGS) Panels
June 2, 2019
ACS CAN responded to the reopening of the Centers for Medicare and Medicaid Services (CMS) coverage decision for NGS testing panels. ACS CAN comments stressed that the existing coverage framework improperly freezes coverage based on current science rather than allowing a framework that could evolve with new, validated use cases for NGS technology.